| NCT Number | NCT07067385 |
| Lead Sponsor | Ruijin Hospital
Collaborators: deepGeneAI, Bio-X Institutes, Shanghai Jiao Tong University |
| Conditions | Personalized Neoantigen Vaccine in Combination With Anti-PD-1 Inhibitors in Standard Therapy-Failed and Adjuvant Therapy, Gastrointestinal Tumors |
| Enrollment | 40 participants |
| Start Date | 2025-07-01 |
| Primary Completion | 2027-12-31 (estimated) |
| Study Completion | 2027-12-31 (estimated) |
| Updated on ClinicalTrials.gov | 2025-07-16 |